ストックスクリーナーアプリを入手
192.23
1.92%
-3.77
アフターアワーズ：
192.23
前日終値:
$196.00
開ける：
$194.5
24時間の取引高:
841.50K
Relative Volume:
0.74
時価総額：
$28.38B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
20.63
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
-0.79%
1か月 パフォーマンス:
+2.76%
6か月 パフォーマンス:
+8.13%
1年 パフォーマンス:
+48.11%
1日の値動き範囲:
$191.67
$195.28
1週間の範囲:
$191.67
$199.80
52週間の値動き範囲:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.23 | 28.94B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,082.20 | 985.37B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.51 | 542.42B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.93 | 384.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 293.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
179.71 | 287.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Lancet publication adds weight to UCB and Biogen lupus drug case - The Pharma Letter
(BIIB) Risk Channels and Responsive Allocation - Stock Traders Daily
Biogen (BIIB) Unveils Positive Phase 3 Findings for Dapirolizuma - GuruFocus
Biogen, UCB Say Lupus Drug Candidate Meets Primary Endpoint in Phase 3 Trial - marketscreener.com
Biogen (BIIB) Drug Trial Achieves Key Endpoint in Lupus Study - GuruFocus
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus - Biogen
UCB and Biogen announce positive DZP phase 3 study results - marketscreener.com
A Look At Biogen (BIIB) Valuation After Earnings Beat And Parkinson’s Setback - simplywall.st
Biogen Inc. stock (US09062X1037): Italian antitrust probe and Parkinson’s trial halt in focus - AD HOC NEWS
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD? - TradingView
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights - GlobeNewswire
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Inc. stock (US09062X1037): RBC price target lift and Italian antitrust probe in focus - AD HOC NEWS
Biogen Announces Webcast of Annual Meeting of Stockholders - Biogen
Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen under investigation by Italian authorities - medwatch.com
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
BIIB Maintained by RBC Capital -- Price Target Raised to $227 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $227 - Moomoo
RBC Lifts Price Target on Biogen to $227 From $222, Keeps Outperform Rating - Moomoo
Italy probes Biogen for allegedly hindering sales of rival's MS drug - Reuters
Italy probes Biogen for allegedly hindering sales of rival’s MS drug - WNWN-FM
Biogen faces Italian antitrust probe (BIIB:NASDAQ) - Seeking Alpha
RBC Capital raises Biogen stock price target on pipeline potential - Investing.com
Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh Cash Flow – BCBA:BIIB.CI - TradingView
Italian Watchdog Probes Biogen Over Alleged Effort to Block MS Biosimilar Rival - NAVLIN DAILY
RBC Capital raises Biogen stock price target on pipeline potential By Investing.com - Investing.com Canada
Discontinued operations of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Debt to equity ratio of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Diluted net income available to common stockholders of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Italy’s antitrust regulator opens probe into US Biogen over alleged dominant position - KFGO
Biogen hit with Italian antitrust probe over multiple sclerosis market - MLex
Antitrust Authority Launches Investigation into Biogen for Multiple Sclerosis Drugs - Agenzia Nova
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position - marketscreener.com
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade) - Seeking Alpha
Biogen Inc. stock (US09062X1037): Alzheimer’s franchise and pipeline in focus after recent develop - AD HOC NEWS
Biogen Inc. (BIIB) Stock Analysis: Navigating a Potential 13% Upside Amidst Robust Drug Pipeline - DirectorsTalk Interviews
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen stock (US09062X1037): Q1 2026 earnings beat rekindles investor interest - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
大文字化:
|
ボリューム (24 時間):